Identification of Biomarkers for Prediction of Response or Resistance Against Target Therapy in Gastric Cancer (VARIANZ)

University of Leipzig

Status: Completed

Conditions: Stomach Neoplasms; Esophageal Neoplasms

Treatments: Other: non-interventional

Study type: Observational

Funder types: Other

Identifiers

NCT02305043

01ZX1310E (Other Grant/Funding Number)

VARIANZ

Details and patient eligibility

About

The aim of this study is to identify biomarkers predicting response or resistance factors of a targeted therapy with trastuzumab in advanced gastric cancer.

Enrollment: 549 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• histologically proven adenocarcinoma of the stomach or gastroesophageal junction

  • stage IV
  • patient receives chemotherapy
  • signed informed consent
  • Age > 18 years

Exclusion criteria

• Patient can not understand meaning and purpose of the study
• patient already received a chemotherapy treatment for advanced disease.